$1.42
-2.1%OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Positive working capital, but relatively tight. The company should monitor cash flow carefully.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
OSTX • NYSE
| OS Therapies Incorporated Balance Sheet | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
ASSETS | |||||
CURRENT ASSETS | |||||
5.5M | 39K | 171.5K | 80.8K | 1.2B | |
5.5M | 39K | 171.5K | 80.8K | 1.2B | |
0.0 | 0.0 | 1.1K | 231.1K | 430.5M | |
0.0 | 0.0 | 1.1K | 231.1K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 430.5M | |
0.0 | 0.0 | 0.0 | 956.0 | 0.0 | |
0.0 | 751.1K | 324.2K | 0.0 | 12.8M | |
5.5M | 790K | 496.8K | 312.8K | 1.7B | |
NON-CURRENT ASSETS | |||||
5.3K | 8.1K | 12.3K | 13.1K | 1.9M | |
5.3K | 8.1K | 12.3K | 13.1K | 1.9M | |
5.5M | 798.1K | 509.1K | 325.9K | 1.7B | |
LIABILITIES | |||||
CURRENT LIABILITIES | |||||
1.7M | 3.1M | 1.4M | 950.3K | 40K | |
1.7M | 2.7M | 1.2M | 856.5K | 40K | |
0.0 | 343.8K | 218.8K | 93.8K | 0.0 | |
618.3K | 2.3M | 1.7M | 934K | 422.8M | |
0.0 | 14.6M | 0.0 | 0.0 | 871.3M | |
0.0 | 0.0 | 426K | 367K | 0.0 | |
2.3M | 4.7M | 3M | 1.6M | 809M | |
4.6M | 24.7M | 6.1M | 3.5M | 2.1B | |
NON-CURRENT LIABILITIES | |||||
0.0 | 0.0 | 10.3M | 7.1M | 5.9B | |
0.0 | 100K | 100K | 100K | 0.0 | |
100K | 0.0 | 1.5M | 1.1M | 0.0 | |
100K | 100K | 11.9M | 8.3M | 5.9B | |
4.7M | 24.8M | 18.1M | 11.8M | 8B | |
SHAREHOLDERS' EQUITY | |||||
6.1M | 1.3K | 1.3K | 1.3K | 0.0 | |
20.9K | 5.3K | 5K | 10K | 8.8M | |
35.1M | 5.5M | 4M | 3.8M | 0.0 | |
-40.4M | -29.5M | -21.6M | -15.2M | -6.3B | |
811.5K | -24M | -17.6M | -11.5M | -6.3B | |
811.5K | -24M | -17.6M | -11.5M | -6.3B | |
SUMMARY | |||||
5.5M | 798.1K | 509.1K | 325.9K | 1.7B | |
0.0 | 14.6M | 10.3M | 7.1M | 6.8B | |
-5.5M | 14.6M | 10.2M | 7M | 5.5B | |
31,841,056 | 31,841,056 | 31,841,056 | 31,841,056 | 31,841,056 |
OSTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 18, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 10, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 21, 2025 | October 21, 2025 | 2025 |
Continue your OSTX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.